Updating results

3533 results

Sort: Relevance | Date

Clostridium difficile infection: fidaxomicin (ESNM1)

Summary of the evidence on fidaxomicin for treating Clostridium difficile (C. diff/C. difficile) infection to inform local NHS planning and decision-making

Evidence summary Published July 2012

Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)

Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making

Evidence summary Published March 2016

Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

Evidence summary Published March 2015

Parkinson's disease with end-of-dose motor fluctuations: opicapone (ES9)

Summary of the evidence on opicapone for reducing end-of-dose motor fluctuations in Parkinson’s disease to inform local NHS planning and decision-making

Evidence summary Published March 2017

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making

Evidence summary Published March 2017

Skin involvement in systemic sclerosis: rituximab (ES7)

Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

Evidence summary Published March 2017

Type 2 diabetes: dulaglutide (ESNM59)

Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published June 2015

Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

Summary of the evidence on budesonide multimatrix (Cortiment) for treating ulcerative colitis (UC) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

Summary of the evidence on aclidinium/formoterol for chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published April 2015

Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)

Summary of the evidence on brinzolamide/brimonidine combination eye drops for treating glaucoma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Asthma: tiotropium (Spiriva Respimat) (ESNM55)

Summary of the evidence on tiotropium (Spiriva Respimat) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Chronic obstructive pulmonary disease: olodaterol (ESNM54)

Summary of the evidence on olodaterol for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

Summary of the evidence on beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) for treating asthma in adults..

Evidence summary Published January 2015

Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making

Evidence summary Published January 2015

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

Summary of the evidence on sucroferric oxyhydroxide for treating hyperphosphataemia in adults with chronic kidney disease (CKD) on dialysis..

Evidence summary Published January 2015

Erectile dysfunction: Alprostadil cream (ESNM50)

Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published December 2014

Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

Summary of the evidence on umeclidinium/vilanterol combination inhaler (Anoro Ellipta) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published November 2014

Schizophrenia: lurasidone (ESNM48)

Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

Evidence summary Published September 2014

Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published September 2014

Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

Evidence summary Published September 2014

Erectile dysfunction: avanafil (ESNM45)

Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published August 2014

Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

Summary of the evidence on telavancin (Vibativ) for hospital-acquired pneumonia caused by MRSA to inform local NHS planning and decision-making

Evidence summary Published July 2014

Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)

Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making

Evidence summary Published July 2014

Parkinson's disease with motor fluctuations: safinamide (ES6)

Summary of the evidence on safinamide for treating Parkinson’s disease with motor fluctuations to inform local NHS planning and decision-making

Evidence summary Published February 2017

Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

Evidence summary Published February 2017

Refractory extrapulmonary sarcoidosis: infliximab (ES4)

Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published January 2017

Oestrogen deficiency symptoms in postmenopausal women: conjugated oestrogens and bazedoxifene acetate (ES3)

Summary of the evidence on conjugated oestrogens and bazedoxifene acetate for oestrogen deficiency symptoms to inform local NHS planning and decision-making

Evidence summary Published December 2016

Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)

Summary of the evidence on doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy in women aged 18 years and older to inform local NHS

Evidence summary Published June 2019

Pulmonary sarcoidosis: infliximab (ES2)

Summary of the evidence on infliximab for treating pulmonary sarcoidosis to inform local NHS planning and decision-making

Evidence summary Published December 2016

Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)

Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS

Evidence summary Published February 2019

Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) (ES18)

Summary of the evidence on fluticasone furoate, umeclidinium and vilanterol (Trelegy) for chronic obstructive pulmonary disease (COPD) to inform local NHS

Evidence summary Published June 2018

Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)

Summary of the evidence on beclometasone, formoterol and glycopyrronium (Trimbow) for chronic obstructive pulmonary disease (COPD) to inform local NHS planning

Evidence summary Published May 2018

Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

Summary of the evidence on ceftazidime/avibactam for complicated intra-abdominal and UTI infections and hospital-acquired pneumonia

Evidence summary: antimicrobial prescribing Published November 2017

Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

Summary of the evidence on adjuvant bisphosphonates for preventing recurrence or improving survival in people with early breast cancer

Evidence summary Published July 2017

Obese, overweight with risk factors: liraglutide (Saxenda) (ES14)

Summary of the evidence on liraglutide for managing obesity and overweight with risk factors in adults to inform local NHS planning and decision-making

Evidence summary Published June 2017

Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

Summary of the evidence on bezlotoxumab for preventing the recurrence of Clostridium difficile (C difficile) infection

Evidence summary Published June 2017

Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)

ES12 Key points The content of this evidence summary

Evidence summary Published April 2017

Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

Evidence summary Published March 2017

Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)

Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making

Evidence summary Published November 2016

Hyperhidrosis: oxybutynin (ES10)

Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

Evidence summary Published March 2017

Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

Summary of the evidence on the levonorgestrel intrauterine delivery system (long-acting reversible contraception) to inform local NHS planning...

Evidence summary Published June 2014

Premature ejaculation: dapoxetine (ESNM40)

Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making

Evidence summary Published May 2014

Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making

Evidence summary Published March 2014

Induction of labour: misoprostol vaginal delivery system (ESNM38)

Summary of the evidence on the misoprostol vaginal delivery system for induction of labour to inform local NHS planning and decision-making

Evidence summary Published March 2014 Last updated November 2014

Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..

Evidence summary Published March 2014

Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)

Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making

Evidence summary Published March 2014

Asthma: fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler (ESNM34)

Summary of the evidence on the fluticasone furoate/vilanterol (Relvar Ellipta) combination inhaler for asthma to inform local NHS planning and decision-making

Evidence summary Published March 2014

Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (ESNM33)

Summary of the evidence on the indacaterol/glycopyrronium (Ultibro Breezhaler) for relieving the symptoms of chronic obstructive pulmonary disease (COPD)..

Evidence summary Published February 2014 Last updated March 2014

Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)

Summary of the evidence on triptorelin (Decapeptyl SR) for treating prostate cancer to inform local NHS planning and decision-making

Evidence summary Published January 2014

Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)

Summary of the evidence on fluticasone/formoterol (Flutiform) combination inhaler for treating asthma to inform local NHS planning and decision-making

Evidence summary Published October 2012